Takeda enters $790m cancer development deal
October 11, 2016Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody
Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …
Roche granted further good news by FDA
October 11, 2016Manufacturing and Production Actembra, Alecensa, FDA, Lucentis, Roche, United States, america
Roche was given further good news by FDA after receiving a Priority Review for its Lucentis drug – this news …
New UK & Ireland general manager for Teva
October 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment
Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …
UAE’s pharmaceutical market projected to grow from $3 billion to $5.7 billion by 2020
October 10, 2016Manufacturing and Production Abu Dhabi, Dubai, GlobalData, United Arab Emires, growth, medical tourism, pharmaceutical market
United Arab Emirates’ pharmaceutical market is set for growth of 13% annually to reach $5.7 billion by 2020, up from …
Educating pharma
October 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency
Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
Roche’s lung cancer success spells competition for BMS’ Opdivo
October 10, 2016Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq
Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …
MSD’s Keytruda twice as successful against standard therapy for lung cancer
October 10, 2016Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda
MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …
Mylan agrees $465m settlement over EpiPen misclassification
October 10, 2016Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen
In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …
Novartis’ new drug muscles in on Pfizer’s territory
October 10, 2016Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib
A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …
NICE recommends Forxiga in Triple Therapy for Diabetes
October 7, 2016Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes
The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …
Cancer Research UK receives ‘success payment’ from GlaxoSmithKline
October 7, 2016Medical Communications GSK, GlaxoSmithKline, University of Manchester, cancer research
CRT and the University of Manchester were rewarded financially for their collaboration developing molecules targeting cancer epigenetics. The agreement between …
Top Ten articles in the Pharma Industry this week
October 7, 2016Medical Communications
The beginning of October has seen the failure of big drugs in clinical trials have a big knock-on effect for …
AstraZeneca sells off third drug in five days
October 7, 2016Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua
AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …
ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal
October 6, 2016Medical Communications Hospira, ICU medical, Pfizer, acquisition, infusion
The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s Hospira Infusion Systems will be …
“Incorrect classification” of EpiPen leads to $1 billion bill for US government
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal
Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …
Teva to sell Allergan’s UK & Ireland generics business for $770m
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva
Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
Alnylam’s shares plunge by 42% after deaths in clinical trials
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran
Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
Novartis axes 175 jobs globally in operations reshuffle
October 5, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
